Aller au contenu principal
Accès ouvert déclaré 2026 article

Towards tuberculosis elimination in people with HIV on antiretroviral therapy: evidence from a two-decade nationwide cohort in Spain

0Citations signalées — pas une note de qualité
9Institutions déclarées
1Pays d’affiliation déclarés

Résumé fourni par la source

BACKGROUND: Tuberculosis (TB) incidence among people with HIV (PWH) has fallen in many high-income settings, yet residual risk persists, and tools to identify those still vulnerable are limited. This study aimed to evaluate TB incidence trends, identify risk factors, and develop a predictive score in PWH in Spain. METHODS: We conducted a retrospective nationwide cohort study using the Spanish AIDS Research Network (CoRIS). Adults initiating antiretroviral therapy (ART) between 2004 and 2023 were followed from ART start until incident TB, death, or censoring. Incidence rates were expressed per 1000 person-years; temporal trends were evaluated across four calendar periods. Independent risk factors were identified with multivariable Cox models, and a predictive score was internally validated with bootstrapping and ROC analysis. RESULTS: Among 16,476 PWH contributing 50,414 person-years, 61 developed TB, yielding an overall incidence of 1.21 cases/1000 person-years (95% CI 0.94-1.56). TB incidence rate declined by 97% between 2004-2008 and 2019-2023 (from 9.1 to 0.2 cases per 1000 person-years; IRR = 0.026, 95% CI 0.004-0.19). Injection-drug use (HR = 2.6, 95% CI 1.21-5.66), low educational attainment (HR = 2.8, 95% CI 1.05-7.51), baseline HIV-RNA viral load > 1 million copies/ml (HR = 1.7, 95% CI 1.00-2.82) and positive latent-TB infection (LTBI) screening (HR = 3.5, 95% CI 1.79-7.01) independently predicted incident TB. A four-variable model showed good discrimination (AUC = 0.71, 95% CI 0.65-0.77). CONCLUSION: Universal ART and comprehensive LTBI management have driven a large decrease in TB incidence in Spanish PWH, but a small subset-characterised by social vulnerability, high viraemia and positive LTBI tests-remains at elevated risk. The validated risk score offers a pragmatic tool to target preventive therapy and surveillance where most needed in low-incidence, high-care settings.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
Towards tuberculosis elimination in people with HIV on antiretroviral therapy: evidence from a two-decade nationwide cohort in Spain
Date Crossref
06/03/2026
Éditeur
Springer Science and Business Media LLC
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude et ne compte pas comme une seconde source scientifique indépendante.

Institutions déclarées

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Sujets associés

Tuberculosis Research and EpidemiologyHIV/AIDS Research and InterventionsPneumocystis jirovecii pneumonia detection and treatment

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.